JP6681390B2 - 腸溶性エラストマー - Google Patents

腸溶性エラストマー Download PDF

Info

Publication number
JP6681390B2
JP6681390B2 JP2017517216A JP2017517216A JP6681390B2 JP 6681390 B2 JP6681390 B2 JP 6681390B2 JP 2017517216 A JP2017517216 A JP 2017517216A JP 2017517216 A JP2017517216 A JP 2017517216A JP 6681390 B2 JP6681390 B2 JP 6681390B2
Authority
JP
Japan
Prior art keywords
polymer
different
same
polymer composite
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017517216A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017519098A5 (OSRAM
JP2017519098A (ja
Inventor
シーイー ザン，
シーイー ザン，
アンドリュー ベリンガー，
アンドリュー ベリンガー，
カルロ ジョバンニ トラバーソ，
カルロ ジョバンニ トラバーソ，
ランガー，　ロバート　エス．
ロバート エス． ランガー，
ディーン リャン グレッティグ，
ディーン リャン グレッティグ，
ローウェル エル． ジュニア ウッド，
ローウェル エル． ジュニア ウッド，
フィリップ エー． エックホフ，
フィリップ エー． エックホフ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54834353&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6681390(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of JP2017519098A publication Critical patent/JP2017519098A/ja
Publication of JP2017519098A5 publication Critical patent/JP2017519098A5/ja
Application granted granted Critical
Publication of JP6681390B2 publication Critical patent/JP6681390B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/40—High-molecular-weight compounds
    • C08G18/42—Polycondensates having carboxylic or carbonic ester groups in the main chain
    • C08G18/4266—Polycondensates having carboxylic or carbonic ester groups in the main chain prepared from hydroxycarboxylic acids and/or lactones
    • C08G18/4269—Lactones
    • C08G18/4277—Caprolactone and/or substituted caprolactone
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
    • C08G18/72—Polyisocyanates or polyisothiocyanates
    • C08G18/73—Polyisocyanates or polyisothiocyanates acyclic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
    • C08G63/08—Lactones or lactides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/005—Hyperbranched macromolecules
    • C08G83/006—After treatment of hyperbranched macromolecules
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L33/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • C08L33/02—Homopolymers or copolymers of acids; Metal or ammonium salts thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L33/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • C08L33/04—Homopolymers or copolymers of esters
    • C08L33/06—Homopolymers or copolymers of esters of esters containing only carbon, hydrogen and oxygen, which oxygen atoms are present only as part of the carboxyl radical
    • C08L33/08—Homopolymers or copolymers of acrylic acid esters
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L33/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • C08L33/04—Homopolymers or copolymers of esters
    • C08L33/14—Homopolymers or copolymers of esters of esters containing halogen, nitrogen, sulfur, or oxygen atoms in addition to the carboxy oxygen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2230/00—Compositions for preparing biodegradable polymers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Prostheses (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2017517216A 2014-06-11 2015-06-11 腸溶性エラストマー Active JP6681390B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462010992P 2014-06-11 2014-06-11
US62/010,992 2014-06-11
PCT/US2015/035425 WO2015191922A1 (en) 2014-06-11 2015-06-11 Enteric elastomers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020000278A Division JP2020056042A (ja) 2014-06-11 2020-01-06 腸溶性エラストマー

Publications (3)

Publication Number Publication Date
JP2017519098A JP2017519098A (ja) 2017-07-13
JP2017519098A5 JP2017519098A5 (OSRAM) 2018-07-19
JP6681390B2 true JP6681390B2 (ja) 2020-04-15

Family

ID=54834353

Family Applications (9)

Application Number Title Priority Date Filing Date
JP2017517216A Active JP6681390B2 (ja) 2014-06-11 2015-06-11 腸溶性エラストマー
JP2016572439A Pending JP2017519003A (ja) 2014-06-11 2015-06-11 自己集合滞留デバイスおよび関連方法
JP2016572445A Active JP6666858B2 (ja) 2014-06-11 2015-06-11 滞留構造体および関連方法
JP2020000278A Pending JP2020056042A (ja) 2014-06-11 2020-01-06 腸溶性エラストマー
JP2020028439A Withdrawn JP2020097623A (ja) 2014-06-11 2020-02-21 滞留構造体および関連方法
JP2020074561A Active JP7337746B2 (ja) 2014-06-11 2020-04-20 自己集合滞留デバイスおよび関連方法
JP2021202475A Active JP7405820B2 (ja) 2014-06-11 2021-12-14 自己集合滞留デバイスおよび関連方法
JP2022197093A Active JP7629898B2 (ja) 2014-06-11 2022-12-09 滞留構造体および関連方法
JP2024227227A Pending JP2025041821A (ja) 2014-06-11 2024-12-24 滞留構造体および関連方法

Family Applications After (8)

Application Number Title Priority Date Filing Date
JP2016572439A Pending JP2017519003A (ja) 2014-06-11 2015-06-11 自己集合滞留デバイスおよび関連方法
JP2016572445A Active JP6666858B2 (ja) 2014-06-11 2015-06-11 滞留構造体および関連方法
JP2020000278A Pending JP2020056042A (ja) 2014-06-11 2020-01-06 腸溶性エラストマー
JP2020028439A Withdrawn JP2020097623A (ja) 2014-06-11 2020-02-21 滞留構造体および関連方法
JP2020074561A Active JP7337746B2 (ja) 2014-06-11 2020-04-20 自己集合滞留デバイスおよび関連方法
JP2021202475A Active JP7405820B2 (ja) 2014-06-11 2021-12-14 自己集合滞留デバイスおよび関連方法
JP2022197093A Active JP7629898B2 (ja) 2014-06-11 2022-12-09 滞留構造体および関連方法
JP2024227227A Pending JP2025041821A (ja) 2014-06-11 2024-12-24 滞留構造体および関連方法

Country Status (19)

Country Link
US (16) US10413507B2 (OSRAM)
EP (5) EP3155024B2 (OSRAM)
JP (9) JP6681390B2 (OSRAM)
KR (2) KR102471095B1 (OSRAM)
CN (4) CN106573999A (OSRAM)
AU (6) AU2015274453A1 (OSRAM)
BR (2) BR122021018078B1 (OSRAM)
CA (3) CA2951884A1 (OSRAM)
DK (2) DK3725357T3 (OSRAM)
ES (2) ES3001020T3 (OSRAM)
FI (2) FI3725357T3 (OSRAM)
IL (1) IL249435B (OSRAM)
MX (2) MX2016016406A (OSRAM)
NZ (1) NZ727659A (OSRAM)
PL (1) PL3725357T3 (OSRAM)
RU (1) RU2766335C2 (OSRAM)
SG (2) SG10201912100SA (OSRAM)
WO (3) WO2015191925A1 (OSRAM)
ZA (1) ZA201608889B (OSRAM)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103948557A (zh) 2014-04-08 2014-07-30 闻晓光 一种新型控释片
KR20170015389A (ko) 2014-06-02 2017-02-08 테바 파마슈티컬 인더스트리즈 리미티드 확장 가능한 위체류 투여 형태
FI3725357T3 (fi) 2014-06-11 2024-12-13 Massachusetts Inst Technology Pidättyviä rakenteita ja niihin liittyviä menetelmiä
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
CA2964900C (en) 2014-09-25 2023-02-21 Progenity, Inc. Electromechanical pill device with localization capabilities
WO2016178971A1 (en) * 2015-05-01 2016-11-10 Massachusetts Institute Of Technology Triggerable shape memory induction devices
EP3153137A1 (en) * 2015-10-06 2017-04-12 Li Galli B.V. Vaginal drug delivery device and vaginal diagnostic device
US10939865B2 (en) * 2015-10-06 2021-03-09 Ligalli B.V. Vaginal drug delivery device and vaginal diagnostic device
AU2016342374B2 (en) * 2015-10-23 2022-08-04 Lyndra Therapeutics, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
CN108601724A (zh) * 2015-12-01 2018-09-28 克雷西奥生物科技有限公司 胃滞留装置
CN108697649A (zh) 2015-12-08 2018-10-23 林德拉有限公司 用于胃驻留系统的几何构型
EP4411037A3 (en) 2015-12-22 2024-11-06 Access Vascular, Inc. High strength biomedical materials
WO2017185003A1 (en) * 2016-04-21 2017-10-26 Massachusetts Institute Of Technology Origami robots and systems
JP7189772B2 (ja) * 2016-05-27 2022-12-14 リンドラ セラピューティクス， インコーポレイティド 胃内滞留システムのための材料構造物
CN109862821A (zh) 2016-09-09 2019-06-07 普罗根尼蒂公司 用于递送可配发物质的机电可摄入装置
CN118766834A (zh) 2016-09-30 2024-10-15 林德拉治疗公司 用于金刚烷类药物缓释的胃驻留系统
EP3320898A1 (en) 2016-11-11 2018-05-16 ratiopharm GmbH Dosage form comprising a carrier structure and method for manufacturing the dosage form
US10737079B2 (en) 2016-12-02 2020-08-11 Clexio Biosciences Ltd. Gastric residence system
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
EP3597258B1 (en) * 2017-03-16 2025-09-03 Terumo Kabushiki Kaisha Catheter assembly
CA3055762A1 (en) 2017-03-31 2018-10-04 Progenity, Inc. Localization systems and methods for an ingestible device
JP7045397B2 (ja) 2017-05-17 2022-03-31 マサチューセッツ インスティテュート オブ テクノロジー 自己復元システムおよび関連構成要素
US11541015B2 (en) 2017-05-17 2023-01-03 Massachusetts Institute Of Technology Self-righting systems, methods, and related components
CA3066658A1 (en) * 2017-06-09 2018-12-13 Lyndra, Inc. Gastric residence systems with release rate-modulating films
JP2020525097A (ja) 2017-06-21 2020-08-27 アクセス・バスキュラー・インコーポレイテッドＡｃｃｅｓｓ Ｖａｓｃｕｌａｒ， Ｉｎｃ． 水溶性ポリマーを組み込んだ高強度ポーラス状材
WO2019032573A1 (en) 2017-08-07 2019-02-14 Finch Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MAINTAINING AND RESTORING A HEALTHY INTESTINAL BARRIER
CN107773554A (zh) * 2017-09-07 2018-03-09 华南农业大学 一种伊维菌素缓释微囊及其制备方法和应用
CA3076330A1 (en) * 2017-09-20 2019-03-28 Lyndra, Inc. Encapsulation of gastric residence systems
WO2019083483A2 (en) * 2017-10-11 2019-05-02 Ege Universitesi A vaginal implant
TWI837082B (zh) * 2017-11-22 2024-04-01 美商萊恩卓治療公司 用於胃滯留系統之材料架構
CN111587088A (zh) * 2017-11-28 2020-08-25 麻省理工学院 胃驻留电子装置
JP7296084B2 (ja) * 2017-12-04 2023-06-22 クレキシオ バイオサイエンシーズ エルティーディー． 長時間作用型胃滞留システム
AU2019269636A1 (en) 2018-05-17 2020-11-19 Massachusetts Institute Of Technology Systems for electrical stimulation
US20190365645A1 (en) * 2018-05-31 2019-12-05 Massachusetts Institute Of Technology Drug delivery articles for gram-level dosing
WO2020036972A1 (en) * 2018-08-15 2020-02-20 Lyndra, Inc. Systems for enteric delivery of therapeutic agents
CA3117947A1 (en) * 2018-11-15 2020-05-22 Massachusetts Institute Of Technology Actuating components and related methods
US11648381B2 (en) 2018-11-15 2023-05-16 Massachusetts Institute Of Technology Thermally controlled residence devices
WO2020102648A1 (en) 2018-11-15 2020-05-22 Massachusetts Institute Of Technology Millineedle systems for esophageal drug delivery
WO2020106704A2 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2020117855A1 (en) 2018-12-03 2020-06-11 Lyndra, Inc. Stomach simulating device
US12194198B2 (en) 2018-12-19 2025-01-14 Access Vascular, Inc. High strength porous materials for controlled release
WO2020160399A1 (en) 2019-02-01 2020-08-06 Massachusetts Institute Of Technology Systems and methods for liquid injection
AU2020240108B2 (en) * 2019-03-20 2025-12-04 Lyndra Therapeutics, Inc. Capsules and capsule coatings for gastric residence dosage forms
CN113840596A (zh) * 2019-03-20 2021-12-24 林德拉治疗公司 用于胃滞留剂型的衣层
WO2020257017A1 (en) * 2019-06-18 2020-12-24 Progenity, Inc. Ingestible device with component capable of residing in the gastrointestinal tract
CN110591125B (zh) * 2019-07-31 2021-01-26 北京理工大学 一种可溶解的三维交联弹性体及其制备和处理方法
AU2020360407A1 (en) * 2019-10-01 2022-04-21 Rani Therapeutics, Llc Self-sizing device for delivering a formulation to a lumen wall
BR112022008908A2 (pt) * 2019-11-08 2022-10-11 Lyndra Therapeutics Inc Sistemas de permanência gástrica para administração de agentes ativos
CA3160660A1 (en) * 2019-11-08 2021-05-14 Lyndra Therapeutics, Inc. Formulations for release-rate modulating films for gastric residence systems
WO2021092484A1 (en) * 2019-11-08 2021-05-14 Lyndra, Inc. Gastric residence systems having arms with controlled stiffness for improved gastric residence
EP4054641A4 (en) * 2019-11-08 2023-12-27 Lyndra Therapeutics, Inc. POLYMERIC LINKERS FOR A STOMACH RESIDENCE SYSTEM
EP4054538A4 (en) * 2019-11-08 2024-02-07 Lyndra Therapeutics, Inc. STOMACH RESIDENCE SYSTEMS WITH A FILAMENT FOR IMPROVED STOMACH RESIDENCE
US11541216B2 (en) 2019-11-21 2023-01-03 Massachusetts Institute Of Technology Methods for manufacturing tissue interfacing components
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
WO2021178785A1 (en) * 2020-03-06 2021-09-10 Access Vascular, Inc. Packaging for hydrated articles and related methods
US11744866B2 (en) 2020-03-18 2023-09-05 Sabine Hazan Methods of preventing and treating COVID-19 infection with probiotics
US11253534B2 (en) 2020-03-23 2022-02-22 Sabine Hazan Method of preventing COVID-19 infection
US11278520B2 (en) 2020-03-31 2022-03-22 Sabine Hazan Method of preventing COVID-19 infection
WO2021231411A1 (en) * 2020-05-12 2021-11-18 Massachusetts Institute Of Technology Gastroretentive articles for alcohol sensing
CN115989054A (zh) 2020-06-30 2023-04-18 阿塞斯血管有限公司 包含标记的制品和相关方法
JP2023536456A (ja) * 2020-07-29 2023-08-25 ザ・セカント・グループ・エルエルシー 架橋ポリ（セバシン酸グリセロール）を含む構造を含む形状誘導型制御放出および保持
CN117615754A (zh) * 2021-05-05 2024-02-27 林德拉治疗公司 包含丁丙诺啡和纳洛酮的胃驻留系统
CA3229117A1 (en) 2021-08-19 2023-02-23 Dorit MIMROD Method of treating parkinson's disease
WO2024073752A2 (en) * 2022-09-30 2024-04-04 Lyndra Therapeutics, Inc. Risperidone dosage regimens with gastric residence systems
WO2024081793A1 (en) 2022-10-12 2024-04-18 Massachusetts Institute Of Technology Ingestible in vivo-assembling drug release formulations and methods
US20240398701A1 (en) * 2023-06-02 2024-12-05 Lyndra Therapeutics, Inc. Manufacturing methods for gastric residence systems
WO2025090468A1 (en) * 2023-10-24 2025-05-01 Soane Pharma LLC Orally ingestible delivery system
CN119971273A (zh) * 2024-01-09 2025-05-13 厦门君德医药科技有限公司 一种胃滞留装置
KR20250121713A (ko) * 2024-02-05 2025-08-12 재단법인대구경북과학기술원 장내 생물학적 물질 다중 채취를 위한 채취 모듈 전달 캡슐
US20250295901A1 (en) * 2024-03-19 2025-09-25 Lyndra Therapeutics, Inc. Flexible line configurations for gastric residence systems
WO2025195482A1 (zh) * 2024-03-22 2025-09-25 厦门君德医药科技有限公司 一种胃滞留装置
WO2025222033A1 (en) * 2024-04-18 2025-10-23 The Regents Of The University Of California Time-controlled payload release capsules

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US415671A (en) * 1889-11-19 harris
US3154461A (en) 1960-03-07 1964-10-27 Minnesota Mining & Mfg Matte-finish polymeric film and method of forming the same
AU449029B2 (en) 1969-08-28 1974-04-17 Commonwealth Scientific And Industrial Research Organisation Device for administration to ruminants
JPS5512411B2 (OSRAM) 1974-03-12 1980-04-02
US4199561A (en) * 1979-02-26 1980-04-22 The Dow Chemical Company Coated nutrients and medicaments for veterinary use
US4451260A (en) 1982-03-26 1984-05-29 Minnesota Mining And Manufacturing Company Sustained release oral medicinal delivery device
US4676507A (en) 1985-05-06 1987-06-30 Patterson Bruce D Puzzles forming platonic solids
US4735804A (en) 1985-05-10 1988-04-05 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
JPS6226215A (ja) * 1985-05-10 1987-02-04 メルク　エンド　カムパニ−　インコ−ポレ−テツド 一定に制御した時間内胃中に保持できる薬剤移送装置
DE3680024D1 (de) * 1985-05-10 1991-08-08 Merck & Co Inc Abgabesystem fuer arzneimittel, das waehrend einer kontrollierten zeitspanne im magen zurueckgehalten werden kann.
US4767627A (en) * 1985-05-29 1988-08-30 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
US4758436A (en) 1985-05-29 1988-07-19 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
EP0253554A3 (en) * 1986-07-15 1988-07-20 Pfizer Inc. Controlled release drug-containing fibers
IL87710A (en) 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
EP0406315B1 (en) 1988-03-24 1992-11-11 Bukh Meditec A/S Controlled release composition
US5002772A (en) 1988-05-31 1991-03-26 Pfizer Inc. Gastric retention system for controlled drug release
NZ228382A (en) * 1989-03-17 1992-08-26 Carter Holt Harvey Plastic Pro Drug administering coil-like device for insertion in body cavity of animal
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
JPH03163011A (ja) * 1989-08-31 1991-07-15 Yamanouchi Pharmaceut Co Ltd 胃内滞留デバイス
US5047464A (en) * 1989-09-20 1991-09-10 Merck & Co., Inc. Bioerodible thermoset elastomers
US5369142A (en) * 1993-01-15 1994-11-29 The Ohio State University Water soluble polymers containing amino acid residues for dental restoratives
WO1995003558A1 (en) 1993-07-19 1995-02-02 Reflexite Corporation Retroreflective structure
DE4406424A1 (de) 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
DE69625831T2 (de) 1995-03-23 2003-11-20 Advanced Animal Technology Ltd., Hamilton Vorrichtung zur Verabreichung einer Substanz
US6962579B2 (en) 1995-03-23 2005-11-08 Advanced Animal Technology Limited Substance delivery device
TW354451B (en) 1995-09-18 1999-03-11 Ibm Method of fabricating cross-linked biobased materials and structures fabricated therewith a method comprising the step of: forming the mixture of polymer and cross-linked agent
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
AU2521797A (en) * 1996-04-12 1997-11-07 Japan Atomic Energy Research Institute Ph-sensitive polymers
GB9616267D0 (en) 1996-08-02 1996-09-11 Ranier Ltd Balloon catheter
WO1999007342A1 (en) 1997-08-11 1999-02-18 Alza Corporation Prolonged release active agent dosage form adapted for gastric retention
DE19850309A1 (de) 1998-10-30 2000-05-04 Lohmann Therapie Syst Lts Expandierbares gastroretensives Therapiesystem mit verlängerter Magenverweildauer
IL133196A0 (en) 1999-11-29 2001-03-19 Yissum Res Dev Co Gastroretentive controlled release pharmaceutical dosage forms
US20020022048A1 (en) 2000-05-26 2002-02-21 Bromberg Lev E. Composite wafer for controlled drug delivery
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US8158143B2 (en) 2000-07-14 2012-04-17 Helmholtz-Zentrum Geesthacht Zentrum Fuer Material- Und Kuestenforschung Gmbh Systems for releasing active ingredients, based on biodegradable or biocompatible polymers with a shape memory effect
US7803392B2 (en) 2000-12-27 2010-09-28 University Of Kentucky Research Foundation pH-Sensitive mucoadhesive film-forming gels and wax-film composites suitable for topical and mucosal delivery of molecules
US6627206B2 (en) 2001-07-25 2003-09-30 Greg A. Lloyd Method and apparatus for treating obesity and for delivering time-released medicaments
IL160363A0 (en) 2001-08-16 2004-07-25 Oregon State Expandable gastric retention device
US20040219186A1 (en) * 2001-08-16 2004-11-04 Ayres James W. Expandable gastric retention device
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
KR100417163B1 (ko) 2001-11-12 2004-02-05 한국과학기술연구원 마이크로 캡슐형 로봇
US20050165136A1 (en) * 2002-01-23 2005-07-28 Uab Research Foundation Glass-ionomer cements containing amino acids
AU2003234159A1 (en) * 2002-04-22 2003-11-03 Purdue Research Foundation Hydrogels having enhanced elasticity and mechanical strength properties
DE10224352A1 (de) 2002-06-01 2003-12-11 Mueller Schulte Detlef Thermosensitive Polymerträger mit veränderbarer physikalischer Struktur für die biochemische Analytik, Diagnostik und Therapie
GB0214013D0 (en) 2002-06-18 2002-07-31 Euro Celtique Sa Pharmaceutical product
MY142179A (en) 2002-07-25 2010-10-15 Glaxo Group Ltd Multicomponent pharmaceutical dosage form
WO2004032906A1 (en) 2002-10-11 2004-04-22 Depomed Development, Ltd. Gastro-retentive levodopa delivery form
EP1594475A1 (en) 2003-02-19 2005-11-16 Mnemoscience GmbH Self-expanding device for the gastrointestinal or urogenital area
JP4497833B2 (ja) * 2003-04-21 2010-07-07 富士フイルム株式会社 ポジ型平版印刷版原版
US7662864B2 (en) * 2003-06-04 2010-02-16 Rutgers, The State University Of New Jersey Solution polymerization processes to prepare a polymer that degrades to release a physiologically active agent
CA2527976C (en) 2003-06-13 2011-11-22 Mnemoscience Gmbh Stents
WO2004112755A1 (en) 2003-06-18 2004-12-29 John Michael Newton Controlled release devices with lumens
US8048169B2 (en) * 2003-07-28 2011-11-01 Baronova, Inc. Pyloric valve obstructing devices and methods
US20090259236A2 (en) 2003-07-28 2009-10-15 Baronova, Inc. Gastric retaining devices and methods
US7790141B2 (en) * 2003-08-11 2010-09-07 Pathak Holdings, Llc Radio-opaque compounds, compositions containing same and methods of their synthesis and use
US6825308B1 (en) * 2003-10-29 2004-11-30 Council Of Scientific And Industrial Research Copolymers and preparation thereof
WO2005056708A2 (en) 2003-12-09 2005-06-23 Spherics, Inc. Bioadhesive polymers with catechol functionality
US20080089933A1 (en) 2006-10-16 2008-04-17 Amir Alon Device and method for reducing calorie intake
EP1773303A2 (en) * 2004-05-25 2007-04-18 Chimeracore, Inc. Self-assembling nanoparticle drug delivery system
DE102004047076A1 (de) 2004-09-28 2006-04-06 Zimmer Ag Verfahren zur Herstellung von Polyestern
IL166183A0 (en) 2005-01-06 2006-01-15 Yissum Res Dev Co Novel diagnostic and imaging techniques of the gi tract
US20060182788A1 (en) * 2005-01-27 2006-08-17 Parminder Singh Hydrophilic biocompatible adhesive formulations and uses
EP1843755B1 (en) 2005-02-01 2015-04-01 Emisphere Technologies, Inc. Gastric retention and controlled release delivery system
US7699863B2 (en) * 2005-03-01 2010-04-20 Tulip Medical Ltd. Bioerodible self-deployable intragastric implants
US7785291B2 (en) 2005-03-01 2010-08-31 Tulip Medical Ltd. Bioerodible self-deployable intragastric implants
JP2006323082A (ja) 2005-05-18 2006-11-30 Canon Inc 現像剤補給容器
US8021384B2 (en) 2005-07-26 2011-09-20 Ram Weiss Extending intrabody capsule
JP4981671B2 (ja) * 2005-08-05 2012-07-25 滋賀県 ポリマーブレンドを含んでなる液中物質捕集材料
US20070048383A1 (en) * 2005-08-25 2007-03-01 Helmus Michael N Self-assembled endovascular structures
WO2007048223A2 (en) 2005-10-25 2007-05-03 Pharmascience Inc. A gastric retention drug delivery system
US8187633B2 (en) * 2005-11-03 2012-05-29 Sun Pharma Advanced Research Company Limited Controlled release coated tablets having prolonged gastric retention
US7674396B2 (en) 2005-11-08 2010-03-09 Plensat Llc Method and system for treatment of eating disorders
US8298574B2 (en) 2006-01-18 2012-10-30 Intec Pharma Ltd. Method and apparatus for forming delivery devices for oral intake of an agent
WO2007093999A1 (en) 2006-02-15 2007-08-23 Intec Pharma Ltd. A gastro-retentive system for the delivery of macromolecules
US20090246142A1 (en) * 2006-03-10 2009-10-01 Massachusetts Institute Of Technology Triggered Self-Assembly of Nanoparticles In Vivo
US7691151B2 (en) 2006-03-31 2010-04-06 Spiration, Inc. Articulable Anchor
US20070264307A1 (en) 2006-05-15 2007-11-15 Medtronic Vascular, Inc. Biodegradable Modified Caprolactone Polymers for Fabricating and Coating Medical Devices
EP1886665A1 (en) 2006-08-01 2008-02-13 Boehringer Ingelheim Pharma GmbH & Co. KG Gastro retentive delivery system
CN101511346B (zh) 2006-09-04 2012-07-04 万能药生物有限公司 可编制的漂浮递送技术
US20080075766A1 (en) 2006-09-25 2008-03-27 Shun-Por Li Multi-core dosage form having transparent outer coating
CA2673511A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
WO2008111077A2 (en) * 2007-03-13 2008-09-18 Technion Research & Development Foundation Ltd. Self-assembled polyhedral multimeric chemical structures
US8507778B2 (en) * 2007-03-13 2013-08-13 Arthur J. Olson Self-assembled polyhedra
WO2008124122A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent and glitazones
MX354603B (es) 2007-05-25 2018-03-13 Indivior Uk Ltd Formulaciones de transferencia sostenida de compuestos de risperidona.
JP2010527712A (ja) * 2007-05-25 2010-08-19 ゴーラム エンタープライゼス エルエルシー 肥満症用の磁気装置およびその製造方法
US8303573B2 (en) * 2007-10-17 2012-11-06 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8038659B2 (en) * 2007-10-17 2011-10-18 The Invention Science Fund I, Llc Disintegrating digestive tract interaction system
CN102105136B (zh) 2008-03-11 2014-11-26 蒂宝制药公司 包含非-阿片类止痛剂和阿片类止痛剂的组合的胃滞留型缓释剂型
US20130273135A1 (en) 2008-03-25 2013-10-17 University Of Utah Research Foundation Controlled Release Combination Biomaterials
KR101601649B1 (ko) 2008-04-18 2016-03-09 인텍 파마 리미티드 카르비도파／레보도파 위체류 약물 전달
US9066877B2 (en) 2008-04-28 2015-06-30 Eat Little Inc. Bezoar-forming units for weight control
US20100256342A1 (en) * 2008-08-12 2010-10-07 Francis Raymond Salemme Protein nodes for controlled nanoscale assembly
KR20110042366A (ko) 2008-08-18 2011-04-26 팀 아카데미 오브 파마슈티컬 사이언스 위장체류 약물 전달 시스템, 제작 방법 및 그것들의 사용
WO2010029095A2 (en) 2008-09-10 2010-03-18 Sandoz Ag Capsule with soluble blocking element
US20110268666A1 (en) 2008-09-29 2011-11-03 Yissum Research Development Company of the Research University of Jerusalem, Ltd. Novel gastroretentive delivery system
EP2378883B1 (en) 2008-12-04 2015-12-23 Intec Pharma Ltd. Zaleplon gastroretentive drug delivery system
EP2373232A2 (en) * 2008-12-27 2011-10-12 Chandra S. Duggirala Devices for treating obesity and methods of using those devices
EP2401225B1 (en) * 2009-02-26 2014-10-22 The Regents of The University of California A supramolecular approach for preparation of size controllable nanoparticles
US8414559B2 (en) 2009-05-07 2013-04-09 Rainbow Medical Ltd. Gastroretentive duodenal pill
DE102009028076A1 (de) 2009-07-29 2011-02-03 Evonik Röhm Gmbh Beschichtungsmittel zum Tauchbeschichten von Kapselhälften
US20110052497A1 (en) * 2009-08-27 2011-03-03 Taris Biomedical, Inc. Minimally Invasive Systems and Methods for In Vivo Testing of Materials
US20110052700A1 (en) 2009-08-31 2011-03-03 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of levosulpiride
WO2011032087A2 (en) 2009-09-11 2011-03-17 Replication Medical Inc. Swellable polymeric device for dietary regulation
US20120321706A1 (en) 2009-10-19 2012-12-20 Intec Pharma Ltd. Novel gastroretentive dosage forms of poorly soluble drugs
US9421169B2 (en) * 2009-11-20 2016-08-23 Covidien Lp Oral dosage forms for delivery of therapeutic agents
CN101711752B (zh) 2009-11-26 2011-09-21 中国科学院上海药物研究所 一种苯并异噁唑类衍生物的控释制剂及其制备方法
EP3461478B1 (en) * 2009-12-24 2020-04-22 Rani Therapeutics, LLC Swallowable drug delivery device
US9498439B2 (en) * 2010-04-15 2016-11-22 Washington University Prodrug compositions, prodrug nanoparticles, and methods of use thereof
US11535510B2 (en) * 2010-04-27 2022-12-27 The Johns Hopkins University Self-folding sub-centimeter structures
BRPI1002601E2 (pt) * 2010-06-01 2020-06-30 Embrapa Pesquisa Agropecuaria composição nanoestruturada de uso veterinário para administração de fármacos
US20120165794A1 (en) 2010-12-22 2012-06-28 Ethicon Endo-Surgery, Inc. Pill Catchers
US20120165792A1 (en) 2010-12-22 2012-06-28 Ethicon Endo-Surgery, Inc. Pill Catchers
US20120165793A1 (en) 2010-12-22 2012-06-28 Ethicon Endo-Surgery, Inc. Pill Catchers
CA2825399A1 (en) 2011-02-04 2012-08-09 Taris Biomedical, Inc. Implantable device for controlled release of low solubility drug
WO2014014348A1 (en) 2012-07-16 2014-01-23 APET Holding B.V. Gastro-retentive drug delivery system
JP2014533975A (ja) 2011-09-26 2014-12-18 ノースイースタン・ユニバーシティ カスタマイズ可能な埋め込みセンサ
US8835507B2 (en) 2012-02-21 2014-09-16 Vymed Corporation Adamantane derivatives possessing anti-viral and anti-microbial activity
US8986337B2 (en) 2012-02-24 2015-03-24 Elwha Llc Devices, systems, and methods to control stomach volume
US9307966B2 (en) 2012-08-15 2016-04-12 St. Jude Medical Puerto Rico Llc Vascular closure device anchor
US20140050784A1 (en) 2012-08-16 2014-02-20 Teva Pharmaceuticals Usa, Inc. Pharmaceutical compositions of memantine
US8746339B2 (en) * 2012-09-27 2014-06-10 Halliburton Energy Services, Inc. Triggerable lost circulation material and method of use
US10441760B2 (en) 2013-03-01 2019-10-15 The Johns Hopkins University Self-actuating chemomechanical devices for delivery and extended release of therapeutic agents in the gastrointestinal tract
CN103654903A (zh) * 2013-11-27 2014-03-26 西安交通大学 一种用于人体消化道吻合的磁性可降解装置
AU2014358675B2 (en) 2013-12-05 2019-10-03 Epitomee Medical Ltd Retentive devices and systems for in-situ release of pharmaceutical active agents
WO2015168297A1 (en) 2014-04-29 2015-11-05 Massachusetts Institute Of Technology Polymeric materials for bio-applications
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
KR20170015389A (ko) 2014-06-02 2017-02-08 테바 파마슈티컬 인더스트리즈 리미티드 확장 가능한 위체류 투여 형태
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
FI3725357T3 (fi) 2014-06-11 2024-12-13 Massachusetts Inst Technology Pidättyviä rakenteita ja niihin liittyviä menetelmiä
WO2016178971A1 (en) 2015-05-01 2016-11-10 Massachusetts Institute Of Technology Triggerable shape memory induction devices
AU2016342374B2 (en) 2015-10-23 2022-08-04 Lyndra Therapeutics, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
CN108697649A (zh) 2015-12-08 2018-10-23 林德拉有限公司 用于胃驻留系统的几何构型
JP7189772B2 (ja) 2016-05-27 2022-12-14 リンドラ セラピューティクス， インコーポレイティド 胃内滞留システムのための材料構造物
CN118766834A (zh) 2016-09-30 2024-10-15 林德拉治疗公司 用于金刚烷类药物缓释的胃驻留系统
US20240390270A1 (en) * 2021-01-19 2024-11-28 Lyndra Therapeutics, Inc. Gastric residence systems for administration of risperidone

Also Published As

Publication number Publication date
AU2015274451A1 (en) 2017-01-12
US20200085736A1 (en) 2020-03-19
US10517820B2 (en) 2019-12-31
CN106573015A (zh) 2017-04-19
MX2016016406A (es) 2017-10-12
RU2017100273A3 (OSRAM) 2018-11-12
BR112016028957A2 (pt) 2017-08-22
US20190298652A1 (en) 2019-10-03
US20200085737A1 (en) 2020-03-19
EP3725357B1 (en) 2024-11-13
EP3155024B1 (en) 2020-09-16
US10413507B2 (en) 2019-09-17
US10849853B2 (en) 2020-12-01
KR102471095B1 (ko) 2022-11-28
JP2017519003A (ja) 2017-07-13
JP6666858B2 (ja) 2020-03-18
JP2022031924A (ja) 2022-02-22
US20190175500A1 (en) 2019-06-13
US20210113460A1 (en) 2021-04-22
ES2832334T3 (es) 2021-06-10
US20190070107A1 (en) 2019-03-07
RU2766335C2 (ru) 2022-03-15
IL249435A0 (en) 2017-02-28
US11389399B2 (en) 2022-07-19
JP7337746B2 (ja) 2023-09-04
AU2015274453A2 (en) 2017-01-19
CN116370644A (zh) 2023-07-04
US10610482B2 (en) 2020-04-07
CN106714893B (zh) 2021-01-01
US10532027B2 (en) 2020-01-14
US20190070108A1 (en) 2019-03-07
IL249435B (en) 2020-08-31
DK3155024T4 (da) 2025-07-21
KR102704895B1 (ko) 2024-09-11
WO2015191920A1 (en) 2015-12-17
KR20220162852A (ko) 2022-12-08
ZA201608889B (en) 2022-04-28
EP4516322A8 (en) 2025-04-16
CA2951884A1 (en) 2015-12-17
NZ727659A (en) 2021-12-24
JP2023022316A (ja) 2023-02-14
EP3155024A1 (en) 2017-04-19
US20200030234A1 (en) 2020-01-30
RU2017100273A (ru) 2018-07-11
AU2015274451B2 (en) 2019-06-20
US20170135954A1 (en) 2017-05-18
US11357723B2 (en) 2022-06-14
FI3725357T3 (fi) 2024-12-13
WO2015191925A8 (en) 2016-02-11
EP3154622A1 (en) 2017-04-19
FI3155024T4 (fi) 2025-07-28
JP2025041821A (ja) 2025-03-26
US10716751B2 (en) 2020-07-21
US20210093564A1 (en) 2021-04-01
JP2017524662A (ja) 2017-08-31
MX2023005223A (es) 2023-05-16
AU2015274456B2 (en) 2020-03-26
AU2015274453A1 (en) 2017-01-12
AU2020200346A1 (en) 2020-02-06
KR20170016960A (ko) 2017-02-14
US20170106099A1 (en) 2017-04-20
US20210177750A1 (en) 2021-06-17
CA2951909C (en) 2022-08-16
AU2015274456A1 (en) 2017-01-12
US11246829B2 (en) 2022-02-15
EP3154553A4 (en) 2018-03-28
EP4516322A3 (en) 2025-05-14
AU2021203086B2 (en) 2023-02-23
BR112016028957B1 (pt) 2021-12-14
DK3725357T3 (da) 2024-12-09
US20170128576A1 (en) 2017-05-11
AU2021203086A1 (en) 2021-06-10
EP4516322A2 (en) 2025-03-05
JP7405820B2 (ja) 2023-12-26
WO2015191922A1 (en) 2015-12-17
US11083690B2 (en) 2021-08-10
US20230039421A1 (en) 2023-02-09
CN106714893A (zh) 2017-05-24
EP3154553B1 (en) 2020-08-05
ES2832334T5 (en) 2025-09-24
AU2019232862A1 (en) 2019-10-10
EP3154553A1 (en) 2017-04-19
CA2951909A1 (en) 2015-12-17
EP3155024B2 (en) 2025-06-18
WO2015191925A1 (en) 2015-12-17
CN106573015B (zh) 2021-11-26
JP2020056042A (ja) 2020-04-09
US10182985B2 (en) 2019-01-22
EP3155024A4 (en) 2018-01-17
CA2951902A1 (en) 2015-12-17
JP7629898B2 (ja) 2025-02-14
WO2015191920A8 (en) 2016-02-04
EP3154622B1 (en) 2020-04-01
CN106573999A (zh) 2017-04-19
SG11201610246PA (en) 2017-01-27
AU2015274451C1 (en) 2019-09-12
EP3154622A4 (en) 2018-01-17
CA2951902C (en) 2022-08-23
US10517819B2 (en) 2019-12-31
DK3155024T3 (da) 2020-11-23
ES3001020T3 (es) 2025-03-04
AU2020200346B2 (en) 2021-08-05
US10716752B2 (en) 2020-07-21
US20210128460A1 (en) 2021-05-06
BR122021018078B1 (pt) 2022-02-08
EP3725357A1 (en) 2020-10-21
SG10201912100SA (en) 2020-02-27
US20190133936A1 (en) 2019-05-09
PL3725357T3 (pl) 2025-03-03
US11077056B2 (en) 2021-08-03
JP2017519098A (ja) 2017-07-13
JP2020114874A (ja) 2020-07-30
JP2020097623A (ja) 2020-06-25

Similar Documents

Publication Publication Date Title
JP6681390B2 (ja) 腸溶性エラストマー
HK1235314B (en) Enteric elastomers
HK1235314A1 (en) Enteric elastomers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180608

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180608

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190813

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200122

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200219

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200323

R150 Certificate of patent or registration of utility model

Ref document number: 6681390

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250